The cost of the monkeys — a proxy for the volume of clinical trials — is projected to reach Rmb150,000 ($21,000) at the start ...
Climate-resilient agriculture uses biotechnology, biofertilizers, biopesticides, genome-edited crops, and AI-driven tools to ...
The company said it expects total revenue of between $450 million and $475 million this year, up from the $290 million to ...
A joint research team of the Korea Advanced Institute of Science and Technology (KAIST) and domestic biotechnology firm ...
Barchart on MSN
The FDA just snubbed Corcept Therapeutics. Should you buy the dip in CORT stock or stay far away?
Corcept Therapeutics (CORT) crashed on Dec. 31 after the Food and Drug Administration (FDA) rejected its application for ...
The unprecedented turmoil at the top U.S. health agencies, under the leadership of Health and Human Services Secretary Robert F. Kennedy Jr., is sure to have a long-term impact on the well-being of ...
ContentsInnovationNew biopolymersFashion demands betterRegulation & policyTrump’s overhaulA new EU bioeconomy ...
13hon MSN
‘Biosecure Act’: New bill forces California biotech firms to cut ties with Chinese companies
Most biotech firms will be forced to reevaluate foreign relationships and re-route supply chains, or hope for a federal ...
The festive period brought some unwanted post for both Sanofi and Corcept Therapeutics in the form of FDA rejections for the ...
Biohaven didn't receive the clinical readout it was hoping for over the festive period. | As the biopharma wound down for the ...
Here, BioSpace looks back at the biggest acquisition deals of 2025. Target: Intra-Cellular Therapies Acquisition date: ...
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. 2, 2026 /CNW/ — Equity Insider News Commentary – The gene therapy market is surging toward $36.55 billion by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback